Drug Trial Radar · NCT05003531
A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Jan 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
250
Actual
Start
Sep 23, 2021
Primary completion
Mar 25, 2022
Study completion Jan 17, 2023
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of IBI112 administered in different dose regimens for the treatment of patients with plaque psoriasis
Conditions
- Psoriasis
Interventions
IBI112 dose 2Drug
Participants will receive placebo or dose 2 IBI112 SC
IBI112 dose 4Drug
Participants will receive placebo or dose 4 IBI112 SC
IBI112 dose 1Drug
Participants will receive placebo or dose 1 IBI112 SC
IBI112 dose 3Drug
Participants will receive placebo or dose 3 IBI112 SC
placeboDrug
Participants will receive placebo SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients achieving Psoriasis Area and severity index(PASI) 90 at week 16Time frame: Week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PeKing University People's Hostpital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.